New Test for Alzheimer’s Disease Touts Possibility of Disease Prevention

By Carolyn Burtt

With an average of one Alzheimer’s disease diagnosis happening every 66 seconds, researchers and medical professionals alike are searching for a tool to prevent or delay the onset of symptoms. Particularly with an aging population, the cost of Alzheimer’s to the American economy is set to rise by almost 400% by 2050.

Dr. McGeer and Aurin Biotech have created a test that measures the amount of peptide amyloid beta protein 42 (Abeta 42) in a patient’s saliva, and have demonstrated there to be a correlation between high concentrations of this peptide and the likelihood of developing Alzheimer’s disease. This test is particularly exciting because it can test patients of any age and determine their risk for Alzheimer’s. Abeta 42 is created throughout the body, but deposits are exclusive to the brain, where it impacts the function and stability of neurons.

Non-steroidal drugs, such as ibuprofen and other common over-the-counter medications, are able to prevent the buildup of Abeta 42 in the brain and the subsequent neuroinflammation and neuron loss. Doctors suggest a daily regiment of non-steroidal drugs for individuals diagnosed with the potential for developing Alzheimer’s, and urge people to test their Abeta 42 levels early to know their personal risk of developing the disease.

 

“Neuroscientists Say Daily Ibuprofen Can Prevent Alzheimer's Disease.” ScienceDaily, ScienceDaily, 26 Mar. 2018,www.sciencedaily.com/releases/2018/03/180326140239.htm.